Follow-up studies on the immune status of patients with Hodgkin's disease after splenectomy and treatment, in relapse and remission.
Sixty-two patients with Hodgkin's disease have been followed for one year from the start of treatment. Immunological assessments were repeated after intensive treatment, in patients relapsing and in those in remission at one year. In patients achieving remission, overall cellular immunity, after deteriorating with therapy, particularly cytotoxic chemotherapy, returned to pre-treatment levels in remission when there was little evidence of cellular immune disturbance. Serum IgG and IgM levels fell with intensive chemotherapy in splenectomized patients. IgA and IgM levels were lower (irrespective of splenectomy or therapy status) in remission than at presentation or after treatment. Relapse or non-response was usually associated with deteriorating cellular immunity. Herpes zoster/varicella and candida infections (seen in 6 patients) were preceded by, or associated with, deterioration of cellular immunity.
D000328:Adult; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000150:complications / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D007136:Immunoglobulins / Q000032:analysis; D007165:Immunosuppression Therapy / Q000009:adverse effects; D013156:Splenectomy
D007136:Immunoglobulins